EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Convergent evolution in nucleocapsid facilitated SARS-CoV-2 adaptation for human infection

Kumari G Lokugamage, Yiyang Zhou, R Elias Alvarado, Jessica A Plante, Yani Ahearn, Jennifer Chen, Leah Estes, William Meyers, Jakob Nilsson, Andrew L Routh iD, David H Walker, Vineet D Menachery iD und 1 weitere

Journal of Virology · 2025

DOI: 10.1128/jvi.02091-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Kumari G Lokugamage und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Coronavirus Nucleocapsid Proteins, Phosphoproteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Human Infections and Immunity University of Texas Medical Branch, University of Texas System, Burroughs Wellcome Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the early stages of the COVID-19 pandemic, several SARS-CoV-2 variants of concern (VOCs) independently acquired mutations in the highly variable 203–205 amino acid region of the nucleocapsid (N) protein including R203K + G204R (found in the Alpha, Gamma, and Omicron variants), R203M (in Delta), and T205I (in Beta). In previous research, we demonstrated that the R203K + G204R mutation significantly enhances SARS-CoV-2 N phosphorylation, which subsequently increases viral fitness and pathogenesis. In this study, we investigated the effects of the R203M and T205I mutations on SARS-CoV-2 infection. Using reverse genetics, we introduced these mutations into the early pandemic Washington-1 (WA-1) strain and observed that both the R203M and T205I mutants enhanced replication and viral fitness. However, unlike the R203K + G204R mutant, the R203M and T205I mutants caused only moderate changes in lung pathology. Notably, each mutation—R203K + G204R, R203M, and T205I—induced distinct patterns of N phosphorylation, which likely contribute to the observed phenotypic differences between the mutants. Interestingly, when bat cells expressing human ACE2 were infected with these mutants, we observed a reduction, rather than an enhancement, in both SARS-CoV-2 replication and N phosphorylation. Collectively, our findings suggest that the R203K + G204R, R203M, and T205I mutations are a result of convergent evolution and reflect how SARS-CoV-2 has adapted for human infection. IMPORTANCE After its emergence, SARS-CoV-2 rapidly adapted to human infection, acquiring numerous mutations across its genome. Many of these mutations remain uncharacterized. This study examines a mutational hotspot among SARS-CoV-2 variants: residues 203–205 of the nucleocapsid (N) protein. We demonstrate that three unique mutations identified in this region among variants of concern enhance infection in human cells and animal models while eliciting distinct patterns of N protein phosphorylation. Intriguingly, these same mutations reduce both N protein phosphorylation and viral replication in bat cells. These findings suggest that each mutation represents independent adaptation by variants of concern for human infection. Importantly, this study underscores the critical role of these mutations in facilitating the expansion of SARS-CoV-2 into human populations and highlights the potential for similar mutations to drive future zoonotic coronavirus outbreaks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Coronavirus Nucleocapsid ProteinsPhosphoproteinsNucleocapsidHumansAnimalsVirus ReplicationMutationPhosphorylationEvolution, MolecularAngiotensin-Converting Enzyme 2Vero CellsChlorocebus aethiopsChiroptera

Stichwörter der Autor:innen

COVID-19SARS-CoV-2nucleocapsidvariants of concern

Substanzen

Coronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsAngiotensin-Converting Enzyme 2ACE2 protein, human

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA.
  • World Reference Center of Emerging Viruses and Arboviruses, The University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, USA.
  • Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Immunology and Microbiology, Scripps Research, La Jolla, California, USA.

ORCID-Profile: Andrew L Routh, Vineet D Menachery, Bryan A Johnson

Förderung

  • Institute of Human Infections and Immunity University of Texas Medical Branch
  • University of Texas System
  • Burroughs Wellcome Fund
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Lokugamage, K. G., Zhou, Y., Alvarado, R. E., Plante, J. A., Ahearn, Y., Chen, J., Estes, L., Meyers, W., Nilsson, J., Routh, A. L., Walker, D. H., Menachery, V. D., & Johnson, B. A. (2025). Convergent evolution in nucleocapsid facilitated SARS-CoV-2 adaptation for human infection. Journal of Virology. https://doi.org/10.1128/jvi.02091-24

Vancouver

Lokugamage KG, Zhou Y, Alvarado RE, Plante JA, Ahearn Y, Chen J, et al. Convergent evolution in nucleocapsid facilitated SARS-CoV-2 adaptation for human infection. Journal of Virology. 2025. doi:10.1128/jvi.02091-24

BibTeX
@article{Lokugamage2025,
  author = {Lokugamage, Kumari G and Zhou, Yiyang and Alvarado, R Elias and Plante, Jessica A and Ahearn, Yani and Chen, Jennifer and Estes, Leah and Meyers, William and Nilsson, Jakob and Routh, Andrew L and Walker, David H and Menachery, Vineet D and Johnson, Bryan A},
  title = {Convergent evolution in nucleocapsid facilitated SARS-CoV-2 adaptation for human infection},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.02091-24}
}
Kostenlos starten →